July 21, 2025
admin
Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate @ Chanakyanipothi.com
+A legacy of 31 Years.
+India`s Oldest Investment & IPO website.
+Most Trusted by Investors across India.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
Listing review of Anthem Biosciences IPO
The IPO is listed on 21 July 2025 @ Rs. 723.05. The listing is marginally below the expectations of the grey market, which anticipated the listing to be at Rs. 743.
Subscription Status
| QIB | B HNI X | S HNI X | NII X | RII X | Total X |
| 192.80 | 51.66 | 30.80 | 44.70 | 5.98 | 67.42 |
| Applications: 37,94,038 | |||||
| Subscription Review: Pace of application has been excellent on the last day |
|||||
Who is the promoter of Anthem Biosciences IPO?
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj and they hold 77.23% of the pre-IPO capital of the company.
What are the Objects of Anthem Biosciences IPO?
The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
What is the business of Anthem Biosciences?
About Anthem Biosciences Limited
Innovating Molecule to Market Since 2006
Founded in 2006, Anthem Biosciences Limited is a cutting-edge, innovation-led Contract Research, Development & Manufacturing Organization (CRDMO). With fully integrated operations spanning drug discovery, development, and commercial manufacturing, it partners with some of the world’s most forward-thinking biotech startups and global pharmaceutical leaders.
Its specialty lies in fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—serving high-impact healthcare markets around the world.
Global Reach. Scientific Depth.
-
44+ countries served, including the U.S., Europe, and Japan
-
550+ customers across CRDMO and specialty ingredients businesses
-
Trusted by both emerging biotech innovators and top-tier pharmaceutical giants
Pipeline Highlights (as of September 30, 2024):
-
196 active R&D and manufacturing projects
-
170 discovery projects (284 molecules synthesized)
-
132 early-phase & 16 late-phase development programs
-
13 commercial manufacturing projects (covering 10 molecules)
-
-
APIs and intermediates manufactured for 10 commercial molecules, all supported from the discovery stage
Intellectual Property & Innovation
-
8 granted patents (1 in India, 7 overseas)
-
24 pending global applications, including key process patents in glycolipid synthesis and GLP-1 analogues
Powered by People
Its team of over 600 skilled professionals includes:
-
Medicinal chemists
-
Microbiologists & molecular biologists
-
Biochemists & chemical engineers
-
In-vivo non-clinical research specialists
Anthem Biosciences is not just a service provider—it is a scientific partner committed to transforming molecules into medicines that impact lives across the globe.
Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate
|
Anthem Biosciences IPO Details |
|
| IPO opens on | 14 July 2025 |
| IPO closes on | 16 July 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 59575250 Shares / Rs 3395 Crore |
| * Fresh Issue | ? Shares / Rs Crore |
| * Offer for Sale | 59575250 shares/ Rs.3395 Crore |
| Face Value per share: | Rs. 2 |
| Price Band | Rs.540-570 |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. 50 per share |
| Retail Lot Size | 26Shares |
| Listing will at | BSE, NSE |
|
Shares offered in |
Shares | Rs. in Crore |
| QIB (50 %) | 29708300 | 1693.38 |
| NII (15 %) | 8912500 | 508.01 |
| RII (35 %) | 20795800 | 1185.36 |
| Employees | 158650 | 8.25 |
| Total Shares | 59561403 | 3395.00 |
| Retail portion will be oversubscribed by | Forms. | |
| How to apply in Anthem Biosciences IPO? | Amount Rs. |
|
| Min Retail Application | 26 Shares | 14820 |
| Max Retail Application | 338 Shares | 192660 |
| Small HNI (Min) | 364 Shares | 207480 |
| Small HNI (Max) | 1742 Shares | 992940 |
| Big HNI Application | 1768 Shares | 1007760 |
|
What is the timetable of Anthem Biosciences IPO? |
|
| IPO opens on | 14 July 2025 |
| IPO Closes on | 16 July 2025 |
| IPO Allotment on | 17 July 2025 |
| Unblocking of ASBA | 18 July 2025 |
| Credit of Shares | 18 July 2025 |
| Listing on | 21 July 2025 |
| Registered Office of Anthem Biosciences | |
| Anthem Biosciences Limited No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099 |
|
| The Lead Managers of the IPO Jm Financial Limited Citigroup Global Markets India Pvt Ltd |
|
| Registrar to IPO | |
| Kfin Technologies Limited |
Anthem Biosciences Financials
| Period Ended | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Revenue | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| Net Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
| Amount in Rs. Crore | |||
Anthem Bioscience
Key Performance Indicators
| KPI | Values |
| ROE | 20.82% |
| ROCE | 26.88% |
| Debt/Equity | 0.05 |
| RoNW | 20.82% |
| PAT Margin | 23.38% |
| EBITDA Margin | 36.81% |
| EPS | 8.07 |
| PE Ratio | 70.63 |
How Anthem Biosciences IPO compares with the Peers?
| Company Name | P/E (x) | RoNW (%) |
| Anthem Biosciences Limited | 70.63 | 20.82 |
| Syngene International Ltd | 51.54 | 11.05 |
| Sai Life Sciences Limited | 92.18 | 10.96 |
| Cohance Lifesciences Limited | 97.29 | 13.61 |
| DIVI’S LABORATORIES Limited | 83.22 | 15.35 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Anthem Biosciences IPO Review
Anthem Biosciences Limited – IPO Review
Established in 2006, Anthem Biosciences Limited is a leading innovation-driven Contract Research, Development & Manufacturing Organization (CRDMO). With end-to-end capabilities in drug discovery, development, and commercial manufacturing, the company partners with cutting-edge biotech startups and global pharmaceutical giants.
Its expertise lies in fermentation-based APIs such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—catering to high-growth healthcare markets worldwide.
🌍 Global Presence & Clientele
-
Operations in 44+ countries, including the U.S., Europe, and Japan
-
Serves over 550 clients across its CRDMO and specialty ingredients businesses
-
Revenue Contribution: 26.42% from North America, 54.61% from Europe
📈 Financial Strength & Growth
-
Consistent topline and bottom-line growth over the past 3 years
-
Declining attrition rates, particularly in R&D, show internal stability
-
Very low debt-equity ratio; the company is on track to be debt-free this year
Though the IPO is priced at a slightly higher valuation, it still offers room for listing gains and long-term appreciation.
✅ Chanakya Recommendation: Apply
- Market Analysis by Nagaraj Shetti
- Stock Market today by Vaishali Parekh
- Analysis by Kotak Securities
- Market Analysis by HDFC Securities
- Technical Analysis by Kotak Securities
- Technical Analysis by Samco Securities
- Reliance, Target & Stoploss
- Gold Analysis
- FII buy-Sell
- Technical Analysis
- Calls for the Day
- Currency Analysis
Quicklinks
